Author: admin

Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non Cystic Fibrosis Bronchiectasis Treatment Landscape @ Non Cystic Fibrosis Bronchiectasis Pipeline Outlook

Key Takeaways from the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
  • DelveInsight’s Non Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non Cystic Fibrosis Bronchiectasis treatment.
  • The leading Non Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Promising Non Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.

Stay informed about the cutting-edge advancements in Non Cystic Fibrosis Bronchiectasis treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Non Cystic Fibrosis Bronchiectasis Clinical Trials Assessment

Non Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

  • Brensocatib: Insmed Incorporated

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Insmed acquired the license for the treatment from AstraZeneca in 2016. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

  • HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.

  • CSL 787: CSL Behring

CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

The Non Cystic Fibrosis Bronchiectasis Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Cystic Fibrosis Bronchiectasis Treatment.
  • Non Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Cystic Fibrosis Bronchiectasis market.

Learn more about Non Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking Non Cystic Fibrosis Bronchiectasis research and development projects @ Non Cystic Fibrosis Bronchiectasis Unmet Needs

Non Cystic Fibrosis Bronchiectasis Companies

Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.

Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Non Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Stay informed about how we’re transforming the future of Respiratory Disease @ Non Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives

Scope of the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • Coverage- Global
  • Non Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Non Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Non Cystic Fibrosis Bronchiectasis Pipeline on our website @ Non Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non‐cystic fibrosis bronchiectasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non‐cystic fibrosis bronchiectasis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Brensocatib: Insmed Incorporated
  9. Mid Stage Products (Phase II)
  10. HSK31858: Haisco Pharmaceutical Group Co., Ltd.
  11. Early Stage Products (Phase I)
  12. CSL 787: CSL Behring
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Non‐cystic fibrosis bronchiectasis Key Companies
  17. Non‐cystic fibrosis bronchiectasis Key Products
  18. Non‐cystic fibrosis bronchiectasis- Unmet Needs
  19. Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers
  20. Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion
  21. Non‐cystic fibrosis bronchiectasis Analyst Views
  22. Non‐cystic fibrosis bronchiectasis Key Companies
  23. 23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics

“Lupus Nephritis Clinical Trials”
DelveInsight’s, “Lupus Nephritis – Pipeline Insight, 2025” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Lupus Nephritis pipeline involves over 35 key companies actively developing more than 40 investigational therapies.

Lupus Nephritis Overview:

Lupus Nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disorder that disrupts immune tolerance, causing systemic autoimmunity and damage to multiple organs.

SLE affects roughly 7.4–159.4 individuals per 100,000, with a prevalence ranging from 1.4% to 21.9%. LN, a form of glomerulonephritis, leads to inflammation and scarring of the kidney’s filtering units (glomeruli) and, in some cases, the entire kidney. The condition is categorized into six histological classes, reflecting different severity levels. The most severe type, proliferative nephritis, results in kidney scarring and impaired function, which can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD), where the kidneys lose their ability to function completely.

Request for a detailed insights report on Lupus Nephritis pipeline insights

“Lupus Nephritis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.

Key Takeaways from the Lupus Nephritis Pipeline Report

  • DelveInsight’s Lupus Nephritis (LN) pipeline report highlights a dynamic landscape, with over 35 companies actively developing more than 40 investigational therapies for LN treatment.

  • Key players in this space include Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others, all working to advance new treatment options for LN. Promising pipeline candidates in various stages of development include Obinutuzumab, ADX-097, NKX019, and additional therapies.

  • In February 2024, the FDA granted Fast Track designation to AlloNK, an experimental natural killer (NK) cell therapy from Artiva Biotherapeutics, for use in combination with rituximab or obinutuzumab in lupus nephritis. This status is intended to accelerate development and review, enabling earlier patient access. AlloNK is designed to boost antibody-dependent cellular cytotoxicity (ADCC), potentially enhancing the effectiveness of existing antibody-based therapies.

Lupus Nephritis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Lupus Nephritis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lupus Nephritis market.

Download our free sample page report on Lupus Nephritis pipeline insights

Lupus Nephritis Emerging Drugs

  • Obinutuzumab: Hoffmann-La Roche

  • ADX-097: Q32 Bio

  • NKX019: Nkarta

Lupus Nephritis Companies

Over 35 leading companies are actively working on therapies for Lupus Nephritis, with Hoffmann-La Roche having a candidate in the most advanced stage, currently in Phase III clinical trials.

DelveInsight’s report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Lupus Nephritis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Lupus Nephritis Therapies and Key Companies: Lupus Nephritis Clinical Trials and advancements

Lupus Nephritis Pipeline Therapeutic Assessment

• Lupus Nephritis Assessment by Product Type

• Lupus Nephritis By Stage

• Lupus Nephritis Assessment by Route of Administration

• Lupus Nephritis Assessment by Molecule Type

Download Lupus Nephritis Sample report to know in detail about the Lupus Nephritis treatment market @ Lupus Nephritis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Lupus Nephritis Current Treatment Patterns

4. Lupus Nephritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Lupus Nephritis Late-Stage Products (Phase-III)

7. Lupus Nephritis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lupus Nephritis Discontinued Products

13. Lupus Nephritis Product Profiles

14. Lupus Nephritis Key Companies

15. Lupus Nephritis Key Products

16. Dormant and Discontinued Products

17. Lupus Nephritis Unmet Needs

18. Lupus Nephritis Future Perspectives

19. Lupus Nephritis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Lupus Nephritis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical, Companies, Therapies, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan

“Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical Trials”
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight highlights that the Nucleic Acid and Gene Therapies pipeline for Neuromuscular Disorders includes over 25 major companies actively working on more than 30 investigational therapies.

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Overview:

Lung cancer continues to be one of the top causes of cancer-related deaths globally and is generally associated with a poor prognosis. The introduction of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand PD-L1 has significantly changed the treatment landscape for non-small cell lung cancer (NSCLC). Blocking the PD-1/PD-L1 pathway has demonstrated strong therapeutic benefits and improved survival outcomes in both preclinical and clinical studies for patients with locally advanced or metastatic NSCLC.

PD-1 is a type I transmembrane protein found on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but have different expression patterns. PD-L1 is expressed on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Both PD-1 and its ligands comprise a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.

Binding of PD-1 to PD-L1 or PD-L2 triggers phosphorylation of two intracellular tyrosine residues, which recruits the phosphatases SHP-1 and SHP-2. These phosphatases interact with PD-1’s ITIM and ITSM motifs, ultimately inhibiting antigen receptor signaling. While this PD-1/ligand interaction suppresses effector T-cell function, the binding of B7-1/B7-2 to CD28 stimulates T-cell proliferation.

Request for a detailed insights report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline insights

“Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapeutics Market.

Key Takeaways from the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Report

  • DelveInsight’s report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders highlights an active pipeline, with over 25 companies developing more than 30 investigational therapies for these conditions.

  • Key players in this space include Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others, all working to advance new treatment options and improve the therapeutic landscape. Promising pipeline candidates in various stages of development include Zimberelimab, PM8002, RPH075, among others.

  • Recent regulatory developments in the broader NSCLC treatment landscape include: In August 2024, the FDA approved AstraZeneca’s durvalumab for adult NSCLC patients post-surgery, extending its use beyond advanced cases where surgery is not feasible. Additionally, in January 2023, pembrolizumab received FDA approval as an adjuvant therapy following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nucleic Acid and Gene Therapies in Neuromuscular Disorders treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Nucleic Acid and Gene Therapies in Neuromuscular Disorders market.

Download our free sample page report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline insightsr

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Emerging Drugs

  • Zimberelimab: Arcus Biosciences

  • PM8002: Biotheus

  • RPH075: R-Pharm

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Companies

Over 25 leading companies are actively working on therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC), with Arcus Biosciences having drug candidates in the most advanced stage, currently in Phase III trials.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapies and Key Companies: Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical Trials and advancements

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Therapeutic Assessment

• Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Product Type

• Nucleic Acid and Gene Therapies in Neuromuscular Disorders By Stage

• Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Route of Administration

• Nucleic Acid and Gene Therapies in Neuromuscular Disorders Assessment by Molecule Type

Download Nucleic Acid and Gene Therapies in Neuromuscular Disorders Sample report to know in detail about the Nucleic Acid and Gene Therapies in Neuromuscular Disorders treatment market @ Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Current Treatment Patterns

4. Nucleic Acid and Gene Therapies in Neuromuscular Disorders – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Late-Stage Products (Phase-III)

7. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Discontinued Products

13. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Product Profiles

14. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Key Companies

15. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Key Products

16. Dormant and Discontinued Products

17. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Unmet Needs

18. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Future Perspectives

19. Nucleic Acid and Gene Therapies in Neuromuscular Disorders Analyst Review

20. Appendix

21. Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical, Companies, Therapies, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan

SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the SYK Inhibitor Treatment Landscape @ SYK Inhibitor Pipeline Outlook

Key Takeaways from the SYK Inhibitor Pipeline Report

  • DelveInsight’s SYK Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for SYK Inhibitor treatment.
  • The leading SYK Inhibitor Companies such as Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
  • Promising SYK Inhibitor Pipeline Therapies such as SKI-O-703, Entospletinib and others.

Stay informed about the cutting-edge advancements in SYK Inhibitor treatments. Download for updates and be a part of the revolution @ SYK Inhibitor Clinical Trials Assessment

SYK Inhibitor Emerging Drugs Profile

  • Cevidoplenib dimesylate: Genosco

The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.

  • HMPL-523: Hutchison MediPharma

An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.

The SYK Inhibitor Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of SYK Inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for SYK Inhibitor Treatment.
  • SYK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • SYK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the SYK Inhibitor market.

Learn more about SYK Inhibitor Drugs opportunities in our groundbreaking SYK Inhibitor research and development projects @ SYK Inhibitor Unmet Needs

SYK Inhibitor Companies

Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.

Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Molecule Type

SYK Inhibitor Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Small molecules
  • Product Type

Stay informed about how we’re transforming the future of SYK landscape @ SYK Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the SYK Inhibitor Pipeline Report

  • Coverage- Global
  • SYK Inhibitor Companies- Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
  • SYK Inhibitor Pipeline Therapies- SKI-O-703, Entospletinib and others.
  • SYK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • SYK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of SYK Inhibitor Pipeline on our website @ SYK Inhibitor Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
  9. Late Stage Products (Phase II/III)
  10. TOP 1630: TopiVert
  11. Mid Stage Products (Phase II)
  12. Cevidoplenib: Genosco
  13. PRT 2761: Portola Pharmaceuticals
  14. Early Stage Products (Phase I/II)
  15. Gusacitinib: Asana BioSciences
  16. Early Stage Products (Phase I)
  17. Mivavotinib: Takeda Oncology
  18. Pre-clinical and Discovery Stage Products
  19. Research programme: small molecule therapeutics: Genosco
  20. Inactive Products
  21. Comparative Analysis
  22. Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline

“Metastatic Non-small Cell Lung Cancer Clinical Trials”
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Metastatic Non-Small Cell Lung Cancer pipeline includes over 25 key companies actively developing more than 30 treatment therapies.

Metastatic Non-small Cell Lung Cancer Overview:

Lung cancer remains a leading cause of cancer-related mortality worldwide, with generally poor outcomes. However, the advent of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has revolutionized treatment for non-small cell lung cancer (NSCLC). Blocking the PD-1/PD-L1 pathway has shown notable therapeutic benefits and improved survival in both preclinical and clinical settings for patients with locally advanced or metastatic NSCLC.

PD-1, a type I transmembrane protein, is expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but exhibit distinct expression patterns. PD-L1 is present on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Structurally, PD-1 and its ligands include a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.

When PD-1 binds to PD-L1 or PD-L2, phosphorylation occurs at two tyrosine residues in its cytoplasmic domain. This triggers recruitment of the phosphatases SHP-1 and SHP-2, which interact with ITIM and ITSM motifs of PD-1, ultimately dampening antigen receptor signaling. This PD-1/ligand interaction suppresses effector T-cell activity, whereas the binding of B7-1/B7-2 to CD28 promotes T-cell proliferation.

Request for a detailed insights report on Metastatic Non-small Cell Lung Cancer pipeline insights

“Metastatic Non-small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Non-small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Metastatic Non-small Cell Lung Cancer Pipeline Report

  • DelveInsight’s report highlights a dynamic Metastatic Non-Small Cell Lung Cancer (NSCLC) pipeline, with over 25 companies actively developing more than 30 investigational therapies. Leading players in this space include Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, among others, all working to advance novel treatment options for metastatic NSCLC.

  • Several promising candidates—such as Zimberelimab, PM8002, RPH075, and others—are progressing through different stages of clinical development.

  • Recent regulatory approvals have further strengthened the treatment landscape. In August 2024, the FDA approved AstraZeneca’s durvalumab for adult NSCLC patients following surgery, broadening its indication beyond advanced cases unsuitable for surgery. Earlier, in January 2023, the FDA approved pembrolizumab as an adjuvant therapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC after surgical resection and platinum-based chemotherapy.

Metastatic Non-small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Metastatic Non-small Cell Lung Cancer Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Non-small Cell Lung Cancer treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Non-small Cell Lung Cancer market.

Download our free sample page report on Metastatic Non-small Cell Lung Cancer pipeline insights

Metastatic Non-small Cell Lung Cancer Emerging Drugs

  • Zimberelimab: Arcus Biosciences

  • PM8002: Biotheus

  • RPH075: R-Pharm

Metastatic Non-small Cell Lung Cancer Companies

Over 25 leading companies are actively working on therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Notably, Arcus Biosciences has drug candidates in the most advanced stage of development, currently in Phase III trials.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Metastatic Non-small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Metastatic Non-small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Non-small Cell Lung Cancer Therapies and Key Companies: Metastatic Non-small Cell Lung Cancer Clinical Trials and advancements

Metastatic Non-small Cell Lung Cancer Pipeline Therapeutic Assessment

• Metastatic Non-small Cell Lung Cancer Assessment by Product Type

• Metastatic Non-small Cell Lung Cancer By Stage

• Metastatic Non-small Cell Lung Cancer Assessment by Route of Administration

• Metastatic Non-small Cell Lung Cancer Assessment by Molecule Type

Download Metastatic Non-small Cell Lung Cancer Sample report to know in detail about the Metastatic Non-small Cell Lung Cancer treatment market @ Metastatic Non-small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Metastatic Non-small Cell Lung Cancer Current Treatment Patterns

4. Metastatic Non-small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Non-small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Metastatic Non-small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Non-small Cell Lung Cancer Discontinued Products

13. Metastatic Non-small Cell Lung Cancer Product Profiles

14. Metastatic Non-small Cell Lung Cancer Key Companies

15. Metastatic Non-small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Metastatic Non-small Cell Lung Cancer Unmet Needs

18. Metastatic Non-small Cell Lung Cancer Future Perspectives

19. Metastatic Non-small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Non-small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline

Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd

“Motor Neuron Disease Clinical Trials”
DelveInsight’s, “Motor Neuron Disease- Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Motor Neuron Disease pipeline involves over 180 key companies actively developing more than 200 investigational therapies.

Motor Neuron Disease Overview:

Motor neuron diseases (MNDs) are a group of progressive neurological disorders that damage motor neurons, the cells responsible for controlling vital muscle functions such as movement, breathing, speech, and swallowing. This group includes conditions like amyotrophic lateral sclerosis (ALS), primary lateral sclerosis, spinal muscular atrophy, and others. Although rare, MND is a serious condition that gradually weakens muscles, profoundly affecting daily activities. While no cure currently exists, treatments can help manage symptoms, and some patients live with the disease for many years. The causes of MND are multifactorial, involving genetic, environmental, and lifestyle factors, with approximately 10% of cases inherited due to genetic mutations.

Symptoms often develop slowly and may be subtle at first. Early indicators include weakness in the legs or ankles, difficulty speaking or swallowing, reduced grip strength, muscle cramps, weight loss, and involuntary emotional reactions such as sudden laughter or crying. The disease typically progresses through three stages—early, middle, and advanced—affecting individuals differently in terms of speed and severity. Ultimately, MND leads to a decline in physical function and reduces life expectancy.

Request for a detailed insights report on Motor Neuron Disease pipeline insights

“Motor Neuron Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Motor Neuron Disease Therapeutics Market.

Key Takeaways from the Motor Neuron Disease Pipeline Report

  • DelveInsight’s Motor Neuron Disease (MND) pipeline report highlights a vibrant landscape, with over 180 companies actively developing more than 200 investigational therapies for MND.

  • Key players in this field include Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc., NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma, and others, all working to advance treatments and improve the therapeutic landscape for MND.

  • Promising pipeline candidates in various stages of development include Talditercept alfa, Pridopidine, VM202, TPN-101, GC 101, VRG 50635, QRL 201, and more.

  • In December 2024, Celosia Therapeutics, a biotech spin-out from Macquarie University, secured $16.8 million in funding to advance its ALS treatment, CTX-1000, into clinical trials. CTX-1000 is a disease-modifying therapy targeting the harmful protein TDP-43, which affects motor neurons in ALS patients. The therapy aims to halt disease progression with a single administration, showing promise even in severe animal models. Human trials are expected to commence by late 2025 at Macquarie University Hospital.

  • In October 2024, Scholar Rock announced positive results from a Phase 3 trial of Apitegromab, a treatment for spinal muscular atrophy (SMA). The therapy demonstrated significant improvements in motor function, with 30.4% of patients showing over a 3-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE), compared to 12.5% on placebo. Scholar Rock plans to submit applications for U.S. Biologics License and European Union marketing authorization in early 2025.

  • In May 2024, the FDA cleared Spinogenix’s Investigational New Drug (IND) application for SPG302, a novel therapy aimed at treating Amyotrophic Lateral Sclerosis (ALS). SPG302 is designed as a once-daily oral treatment with the potential to regenerate synapses, thereby addressing declines in cognitive and motor functions associated with ALS.

Motor Neuron Disease Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Motor Neuron Disease Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Motor Neuron Disease treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Motor Neuron Disease market.

Download our free sample page report on Motor Neuron Disease pipeline insights

Motor Neuron Disease Emerging Drugs

  • Talditercept alfa: Biohaven Pharmaceuticals, Inc.

  • Pridopidine: Prilenia Therapeutics

  • VM202: Helixmith Co., Ltd.

  • TPN-101: Transposon Therapeutics, Inc.

  • GC 101: GeneCradle Therapeutics

  • VRG 50635: Verge Genomics

  • QRL 201: QurAlis Corporation

Motor Neuron Disease Companies

Over 180 leading companies are actively pursuing therapies for Motor Neuron Disease, with Biohaven Pharmaceuticals, Inc. having a candidate in the most advanced stage, currently undergoing Phase III clinical trials.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Motor Neuron Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Motor Neuron Disease Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Motor Neuron Disease Therapies and Key Companies: Motor Neuron Disease Clinical Trials and advancements

Motor Neuron Disease Pipeline Therapeutic Assessment

• Motor Neuron Disease Assessment by Product Type

• Motor Neuron Disease By Stage

• Motor Neuron Disease Assessment by Route of Administration

• Motor Neuron Disease Assessment by Molecule Type

Download Motor Neuron Disease Sample report to know in detail about the Motor Neuron Disease treatment market @ Motor Neuron Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Motor Neuron Disease Current Treatment Patterns

4. Motor Neuron Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Motor Neuron Disease Late-Stage Products (Phase-III)

7. Motor Neuron Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Motor Neuron Disease Discontinued Products

13. Motor Neuron Disease Product Profiles

14. Motor Neuron Disease Key Companies

15. Motor Neuron Disease Key Products

16. Dormant and Discontinued Products

17. Motor Neuron Disease Unmet Needs

18. Motor Neuron Disease Future Perspectives

19. Motor Neuron Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Motor Neuron Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd

Recurrent Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent Glioblastoma Research. Learn more about our innovative pipeline today! @ Recurrent Glioblastoma Pipeline Outlook

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

  • On 20 August 2025, CarThera conducted a study of brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated.
  • On 17 August 2025, Darell Bigner announced a study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
  • On 15 August 2025, University of Pennsylvania organized a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
  • DelveInsight’s Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
  • The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
  • Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.

Stay informed about the cutting-edge advancements in Recurrent Glioblastoma treatments. Download for updates and be a part of the revolution in care @ Recurrent Glioblastoma Clinical Trials Assessment

Recurrent Glioblastoma Emerging Drugs Profile

  • ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

  • GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

  • Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

  • VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

The Recurrent Glioblastoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent Glioblastoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent Glioblastoma Treatment.
  • Recurrent Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Recurrent Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent Glioblastoma Market

Stay informed about the Recurrent Glioblastoma Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Recurrent Glioblastoma Unmet Needs

Recurrent Glioblastoma Companies

Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Recurrent Glioblastoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Transform your understanding of the Recurrent Glioblastoma Pipeline! See the latest progress in drug development and clinical research @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent Glioblastoma Pipeline Report

  • Coverage- Global
  • Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
  • Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
  • Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Recurrent Glioblastoma Pipeline Analysis Today! @ Recurrent Glioblastoma Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Recurrent Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ASC40: Ascletis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GX-I7: Genexine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VXM01: VAXIMM AG
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Recurrent Glioblastoma Key Companies
  21. Recurrent Glioblastoma Key Products
  22. Recurrent Glioblastoma- Unmet Needs
  23. Recurrent Glioblastoma- Market Drivers and Barriers
  24. Recurrent Glioblastoma- Future Perspectives and Conclusion
  25. Recurrent Glioblastoma Analyst Views
  26. Recurrent Glioblastoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-glioblastoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Asperger Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside

“Asperger Syndrome Market”
The leading Asperger Syndrome Companies working in the market include Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others.

 

Emerging therapies for Asperger Syndrome are anticipated to drive growth in the Asperger Syndrome market in the coming years.

 

DelveInsight has launched a new report on “Asperger Syndrome – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Asperger Syndrome, historical and forecasted epidemiology as well as the Asperger Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request for our detailed sample pages on Asperger Syndrome Market report

 

 

Some of the key facts of the Asperger Syndrome Market Report:

 

  • The Asperger Syndrome market is anticipated to grow as awareness of the condition rises and more effective treatments and interventions are introduced.

  • Key companies operating in this market include Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., among others.

  • In June 2023, the State University of New York – Upstate Medical University announced a clinical trial study focused on salivary collection and the Mullen Scales of Early Learning. The research aims to validate a set of miRNAs capable of distinguishing children with autism spectrum disorder (ASD) from those who have a positive MCHAT-R result but do not have ASD. These biomarkers could enable earlier autism detection, leading to timely interventions, while also enhancing our understanding of neurological changes associated with autism in children.

 

Key benefits of the Asperger Syndrome market report:

  1. Asperger Syndrome market report covers a descriptive overview and comprehensive insight of the Asperger Syndrome Epidemiology and Asperger Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Asperger Syndrome market report provides insights on the current and emerging therapies.

  3. Asperger Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Asperger Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Asperger Syndrome market.

 

Got queries? Click here to know more about the Asperger Syndrome Market Landscape

 

 

Asperger Syndrome Overview

 

Asperger Syndrome, a developmental disorder on the autism spectrum, is generally managed using a personalized, multidisciplinary approach. Treatment aims to enhance social communication, address sensory sensitivities, and manage co-occurring conditions. Behavioral interventions, including Applied Behavior Analysis (ABA) and social skills training, play a key role in helping individuals improve social interactions and build relationships. Available therapies encompass both traditional and modern medical approaches, with established treatment guidelines and protocols followed in regions such as the United States, Europe, and Japan.

 

Asperger Syndrome Market Outlook

 

The Asperger Syndrome market is expected to undergo significant changes in the coming years, driven by the anticipated introduction of emerging therapies from leading companies such as Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others during the 2020–2034 forecast period.

 

Discover how the asperger syndrome market is rising in the upcoming years

 

 

Asperger Syndrome Key Companies: Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc.

 

Scope of the Asperger Syndrome Market Report

 

  • Study Period: 2020-2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Asperger Syndrome Companies: Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others

  • Asperger Syndrome Therapeutic Assessment: Asperger Syndrome current marketed and Asperger Syndrome emerging therapies

  • Asperger Syndrome Market Dynamics: Asperger Syndrome market drivers and Asperger Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Asperger Syndrome Unmet Needs, KOL’s views, Analyst’s views, Asperger Syndrome Market Access and Reimbursement

 

Download sample pages @ https://www.delveinsight.com/sample-request/asperger-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

 

Table of Contents

 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Asperger Syndrome Patient Share (%) Overview at a Glance

5. Asperger Syndrome Market Overview at a Glance

6. Asperger Syndrome Disease Background and Overview

7. Asperger Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Asperger Syndrome

9. Asperger Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Asperger Syndrome Emerging Therapies

12. Asperger Syndrome Market Outlook

13. Country-Wise Asperger Syndrome Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Asperger Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Click here to read more about Asperger Syndrome Market Outlook 2034

 

Related Reports:

Asperger Syndrome Pipeline Insights, DelveInsight

“Asperger Syndrome Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asperger Syndrome market. A detailed picture of the Asperger Syndrome pipeline landscape is provided, which includes the disease overview and Asperger Syndrome treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asperger Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside

Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory Syncytial Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Respiratory Syncytial Virus Pipeline. Dive into DelveInsight’s comprehensive report today! @ Respiratory Syncytial Virus Pipeline Outlook

Key Takeaways from Respiratory Syncytial Virus Pipeline Report

  • On 19 August 2025, ModernaTX Inc. announced a study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months.
  • On 17 August 2025, Shenzhen Shenxin Biotechnology Co., Ltd conducted a study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
  • On 14 August 2025, Pfizer conducted a phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
  • DelveInsight’s Respiratory Syncytial Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Respiratory Syncytial Virus treatment.
  • The leading Respiratory Syncytial Virus Companies such as AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
  • Promising Respiratory Syncytial Virus Pipeline Therapies such as JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.

Stay ahead with the most recent pipeline outlook for Respiratory Syncytial Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Respiratory Syncytial Virus Treatment Drugs

Respiratory Syncytial Virus Emerging Drugs Profile

  • Clesrovimab: Merck Sharp & Dohme

Clesrovimab (MK-1654) is an investigational extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV-associated medically attended lower respiratory infection (MALRI). Clesrovimab is being studied in infants (pre-term and full-term) to provide rapid, durable protection through their first RSV season with a single, fixed-dose administration. Currently, the drug is in the Phase III stage of its development for the treatment of Respiratory Syncytial Virus (RSV). 

  • IVX A12: AstraZeneca

IVX-A12 is a potential bivalent first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses. The FDA has granted IVX-A12 Fast Track designation in adults ≥60 years of age. IVX-A12 is a liquid, refrigerator-stable formulation comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate. Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial. The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial. Currently, the drug is in the Phase II stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

  • MV-012-968: Meissa Vaccines, Inc

MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants from RSV. MV-012-968 is well-tolerated, highly attenuated, and induces a strong systemic and mucosal IgA antibody response in RSV-naïve children. Meissa is currently enrolling participants between the ages of six and 36 months in a Phase Ic clinical study at multiple sites in the U.S. to evaluate the safety and immunogenicity of MV-012-968. MV-012-968 was generated using the company’s proprietary AttenuBlockTM synthetic biology platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. Currently, the drug is in the Phase I stage of its development for the treatment of Respiratory Syncytial Virus (RSV).

The Respiratory Syncytial Virus Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
  • Respiratory Syncytial Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market

Explore groundbreaking therapies and clinical trials in the Respiratory Syncytial Virus Pipeline. Access DelveInsight’s detailed report now! @ New Respiratory Syncytial Virus Drugs

Respiratory Syncytial Virus Companies

AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Respiratory Syncytial Virus Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Respiratory Syncytial Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Respiratory Syncytial Virus Market Drivers and Barriers

Scope of the Respiratory Syncytial Virus Pipeline Report

  • Coverage- Global
  • Respiratory Syncytial Virus Companies- AstraZeneca, Daiichi Sankyo Company, Moderna Therapeutics, Enanta Pharmaceuticals, Codagenix, Inc., Meissa Vaccines, Inc., Calder Biosciences, Ark Biosciences, Vicebio, Immorna, CastleVax and others.
  • Respiratory Syncytial Virus Pipeline Therapies- JNJ-53718678 2.5 mg/kg, Clesrovimab, RSV-A Memphis 37b, Matrix-M1 Adjuvant and others.
  • Respiratory Syncytial Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Respiratory Syncytial Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Respiratory Syncytial Virus Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Respiratory Syncytial Virus Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Respiratory Syncytial Virus (RSV): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Respiratory Syncytial Virus (RSV) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Clesrovimab: Merck Sharp & Dohme
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. IVX A12: AstraZeneca
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. MV-012-968: Meissa Vaccines, Inc
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Respiratory Syncytial Virus (RSV) Key Companies
  23. Respiratory Syncytial Virus (RSV) Key Products
  24. Respiratory Syncytial Virus (RSV)- Unmet Needs
  25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
  26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
  27. Respiratory Syncytial Virus (RSV) Analyst Views
  28. Respiratory Syncytial Virus (RSV) Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “JAK Inhibitor Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in JAK Inhibitor pipeline landscape. It covers the JAK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitor therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive JAK Inhibitor pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive JAK Inhibitor Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ JAK Inhibitor Pipeline Outlook Report

Key Takeaways from the JAK Inhibitor Pipeline Report

  • On 19 August 2025, Geron Corporation announced a study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
  • On 14 August 2025, Pfizer announced a Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
  • On 12 August 2025, Incyte Corporation conducted a study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
  • DelveInsight’s JAK Inhibitor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitor treatment.
  • The leading JAK Inhibitor Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
  • Promising JAK Inhibitor Therapies such as Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others

Discover how the JAK Inhibitor treatment paradigm is evolving. Access DelveInsight’s in-depth JAK Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ JAK Inhibitor Clinical Trials and Studies

JAK Inhibitor Emerging Drugs Profile

  • Povorcitinib: Incyte Corporation

Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.

  • CPL409116: Celon Pharma

CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.

  • ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.

  • SDC 1802: Sareum

SDC-1802 is an investigational Sareum’s TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.

The JAK Inhibitor Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitor Treatment.
  • JAK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • JAK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitor market.

Get a detailed analysis of the latest innovations in the JAK Inhibitor pipeline. Explore DelveInsight’s expert-driven report today! @ JAK Inhibitor Unmet Needs

JAK Inhibitor Companies

Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.

JAK Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

JAK Inhibitor Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming JAK Inhibitor Therapies and key JAK Inhibitor Developments @ JAK Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the JAK Inhibitor Pipeline Report

  • Coverage- Global
  • JAK Inhibitor Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
  • Promising JAK Inhibitor Therapies – Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others
  • JAK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • JAK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in JAK Inhibitor drug development? Find out in DelveInsight’s exclusive JAK Inhibitor Pipeline Report—access it now! @ JAK Inhibitor Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Janus Kinase (JAK) Inhibitor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Janus Kinase (JAK) Inhibitor– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Povorcitinib: Incyte Corporation
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CPL409116: Celon Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ATI-2138: Aclaris Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SDC 1802: Sareum
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Janus Kinase (JAK) Inhibitor Key Companies
  21. Janus Kinase (JAK) Inhibitor Key Products
  22. Janus Kinase (JAK) Inhibitor- Unmet Needs
  23. Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
  24. Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
  25. Janus Kinase (JAK) Inhibitor Analyst Views
  26. Janus Kinase (JAK) Inhibitor Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: JAK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies